iVeena Completes Phase I/IIa Study of IVMED-10 for Post-Cataract Inflammation

November 17, 2017: By Jon Swedien

iVeenaiVeena Delivery Systems has successfully completed a pilot clinical trial for its lead product, IVMED-10, a bioerodible implant that treats pain and inflammation after cataract surgery, the Salt Lake City-based company announced Nov. 8.

IVMED-10 is a sustained release implant, based on the company’s intracapsular drug delivery platform, that delivers dexamethasone for two weeks. The device is placed in the lens capsule during the time of cataract surgery. It is intended for patients undergoing routine cataract extraction, iVeena said.

Eight patients were enrolled in the Phase I/IIa, single-site, single-arm, open-label clinical study. iVeena said an independent clinical trial report found IVMED-10 was safe and effective for the control of inflammation typically observed following cataract surgery. Retinal thickness outcomes were comparable to published data of nonsteroidal anti-inflammatory drugs and steroid standard of care therapy. All adverse events, including elevated intraocular pressure, corneal edema, and pain, were transient in nature. All patients had 20/25 best-corrected visual acuity or better at the end of the study, iVeena said.

iVeena has additional clinical studies of IVMED-10 planned for Q1-2018.

The company is also developing IVMED-20, a sustained release implant that delivers dexamethasone for six weeks. The product is placed in the lens capsule at the time of cataract surgery and is intended for patients that are at risk of developing retinal thickening in association with cataract extraction.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Ivantis Gains US FDA Approval for Hydrus Microstent

US FDA Approves Sun Pharma’s CEQUA for Dry Eye

Regeneron Receives US FDA Approval for 12-Week Eylea Dosing

STAAR, Japan’s Shinjuku LASIK Clinic Sign Multiyear Agreement

Alcon Launches Finesse Sharkskin ILM Forceps

Imprimis’ Q2-2018 Revenues Increase 51 Percent to $10.4 Million

Bausch Health Revenues in Q2-2018 Drop 5 Percent

TearLab’s Q2-2018 Revenues Drop 8.5 Percent to $6.4 Million

DeepMind AI System Accurately Detects Eye Disease in OCT Scans at Moorfields

Study by MIT, Mass Eye and Ear Suggests Glaucoma is Autoimmune Disease

Study Indicates Insulin May Restore Vision in Glaucoma

CHOP Researchers Define Six ROP Indicators

Nicox Initiates Phase II Study of NCX 470 in Open-Angle Glaucoma, Ocular Hypertension

Eyenovia’s Microdose Latanoprost Delivers Drug with Precision, Lowers IOP in Proof-of-Concept Study

Rayner to Launch Sulcoflex Trifocal Toric IOL in September

CMS Allows Medicare Advantage Plans to Apply Step Therapy to Retinal Injections

Glaukos Reports Drug Collaboration with D. Western, Q2-2018 Net Sales Increase of 5 Percent

Allergan Will Co-develop Editas’ CRISPR Genome Editing Candidate for LCA10

Spark Reports Q2-2018 Net Sales of $4.3 Million for Luxturna

Aerie’s Rhopressa Posts $2.4 Million in Net Revenues in Q2-2018

Coming soon

2018 Ophthalmic Laser Report: A Global Market Analysis for 2017 to 2023 (Photocoagulation, Photodisruption, and SLT